Jeffrey Sevigny appointed as CMO of Rapport Therapeutics
US biotech company Rapport Therapeutics (Nasdaq: RAPP) recently appointed Dr. Jeffrey Sevigny as its chief medical officer (CMO). Dr. Sevigny, a physician-scientist with over 15 years of experience in translational and clinical drug development, has been a key figure in groundbreaking research in neuroscience and rare diseases. His expertise covers the entire drug development spectrum, from initial discovery to advanced clinical trials and regulatory clearance. With a proven track record in portfolio management and organizational leadership, Dr. Sevigny brings a wealth of strategic and operational knowledge to Rapport’s team.
Dr. Sevigny transitions to Rapport from his previous role as the chief medical officer at Prevail Therapeutics, a subsidiary of Eli Lilly (NYSE: LLY). During his tenure at Prevail, he established and led the clinical development department and played a crucial role in the company’s achievements, including securing financing rounds, conducting an IPO, and facilitating the acquisition by Lilly. His appointment at Rapport signifies a strategic move to further enhance the company’s capabilities and drive innovation in the biotech sector.
By introducing Dr. Sevigny as CMO, Rapport is poised to leverage his expertise to advance its research and development initiatives. His extensive experience in various facets of the drug development process, coupled with his ability to build high-performing teams, positions him as a valuable asset to the company. With a focus on driving scientific innovation and translating research into tangible therapeutic solutions, Dr. Sevigny’s appointment underscores Rapport’s commitment to advancing patient care through cutting-edge medical interventions.
Rapport’s decision to bring Dr. Sevigny on board reflects the company’s dedication to fostering innovation and excellence in the biopharmaceutical industry. By appointing a seasoned professional with a proven track record in driving clinical development and achieving regulatory milestones, Rapport aims to strengthen its position as a leader in the field. Dr. Sevigny’s leadership will be instrumental in guiding Rapport through the next phase of growth and expanding its portfolio of novel treatments for unmet medical needs.
With the addition of Dr. Sevigny to its leadership team, Rapport is poised to capitalize on his strategic insights and operational acumen to drive value creation and sustainable growth. His proven ability to navigate complex regulatory landscapes and lead successful drug development programs will be pivotal in shaping Rapport’s future trajectory. As the company continues to advance its pipeline of innovative therapies and explore new avenues for therapeutic innovation, Dr. Sevigny’s appointment signals a new chapter of growth and discovery for Rapport Therapeutics.
